Lexicon Pharmaceuticals, Inc (LXRX)

Etorro trading 970x250
Lexicon Pharmaceuticals, Inc (LXRX) Logo

About Lexicon Pharmaceuticals, Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. Address: 8800 Technology Forest Place, The Woodlands, TX, United States, 77381-1160

Lexicon Pharmaceuticals, Inc News and around…

Latest news about Lexicon Pharmaceuticals, Inc (LXRX) common stock and company :

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
06 Oct, 2021 FinancialContent

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market ...

Why Cramer Likes Bank of America, Ethereum And More
06 Oct, 2021 FinancialContent

On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Bank of America Corp (NYSE: BAC). He met the CFO over the ...

Take a Pass on Lexicon Pharmaceuticals for Now
06 Oct, 2021 Yahoo! Finance

During Tuesday's Mad Money "Lightning Round", one caller asked Jim Cramer about a company by the name of Lexicon Pharmaceuticals : "I like companies like this," he responded. Let's check out the chart of this biopharmaceutical company that is using gene science. In this daily bar chart of LXRX, below, we can see that prices made a rapid run-up in late 2020 and then declined from February to July/August.

LXRX Crosses Above Key Moving Average Level
24 Sep, 2021 FinancialContent

In trading on Friday, shares of Lexicon Pharmaceuticals, Inc. (LXRX) crossed above their 200 day moving average of $5.10, changing hands as high as $5.31 per share..

Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
15 Sep, 2021 FinancialContent
6 Penny Stocks To Buy According To Analysts, Targets Up To 322%
31 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Pre-Market Session
30 Aug, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) stock rose 17.45% to $45.22 during Monday's pre-market session. The market value of ...

Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
30 Aug, 2021 FinancialContent
60 Biggest Movers From Friday
30 Aug, 2021 FinancialContent

Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss ...

Lexicon Touts Analyses From Two Phase 3 Trials Of Its Heart Failure Drug
23 Aug, 2021 FinancialContent

Lexicon Pharmaceuticals Inc(NASDAQ: LXRX) haspresented additional analysesfrom SOLOIST and SCORED Phase 3 trials ...

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials
23 Aug, 2021 FinancialContent
Overview Of Value Stocks In The Healthcare Sector
16 Aug, 2021 FinancialContent

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
30 Jul, 2021 Yahoo! Finance

Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and 680.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
30 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Lexicon Pharmaceuticals: Q2 Earnings Insights
30 Jul, 2021 FinancialContent

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were unchanged after the company reported Q2 results. Quarterly ...

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer
30 Jul, 2021 FinancialContent
Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
30 Jul, 2021 FinancialContent

Conference Call and Webcast at 8:00 am Eastern Time

Earnings Scheduled For July 30, 2021
30 Jul, 2021 FinancialContent

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its ...

Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021
28 Jul, 2021 FinancialContent
Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know
22 Jul, 2021 Yahoo! Finance

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12 Health Care Stocks Moving In Friday's Pre-Market Session
16 Jul, 2021 FinancialContent

Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The ...

Notable Two Hundred Day Moving Average Cross - LXRX
01 Jul, 2021 FinancialContent

In trading on Thursday, shares of Lexicon Pharmaceuticals, Inc. (LXRX) crossed below their 200 day moving average of $4.33, changing hands as low as $4.26 per share..

First Week of August 20th Options Trading For Lexicon Pharmaceuticals (LXRX)
28 Jun, 2021 FinancialContent

Investors in Lexicon Pharmaceuticals, Inc. (LXRX) saw new options become available this week, for the August 20th expiration..

55 Biggest Movers From Friday
28 Jun, 2021 FinancialContent

Gainers IKONICS Corporation (NASDAQ: IKNX) shares surged 64.3% to close at $18.56 on Friday after the company reported a merger ...

Noteworthy Friday Option Activity: LXRX, SNCR, OLED
25 Jun, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Lexicon Pharmaceuticals, Inc. (LXRX), where a total of 9,338 contracts have traded so far, representing approximately 933,800 underlying shares..

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions
25 Jun, 2021 FinancialContent
Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference
26 May, 2021 FinancialContent
Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology’s 70th Annual Scientific Session
13 May, 2021 FinancialContent
First Week of LXRX June 18th Options Trading
07 May, 2021 FinancialContent

Investors in Lexicon Pharmaceuticals, Inc. (LXRX) saw new options become available this week, for the June 18th expiration..

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates
07 May, 2021 Yahoo! Finance

Lexicon (LXRX) delivered earnings and revenue surprises of 11.76% and -99.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals, Inc (LXRX) is a NASDAQ Common Stock listed in , ,

970x250